Titre : Benzazépines

Benzazépines : Questions médicales fréquentes

Nom anglais: Benzazepines

Descriptor UI: D001552

Tree Number: D03.633.100.079

Termes MeSH sélectionnés :

Norepinephrine

Questions fréquentes et termes MeSH associés

Diagnostic 5

#1

Comment diagnostiquer une dépendance aux benzazépines ?

Le diagnostic repose sur l'historique d'utilisation, les symptômes de sevrage et les comportements compulsifs.
Dépendance aux médicaments Benzodiazépines
#2

Quels tests sont utilisés pour évaluer l'usage des benzazépines ?

Des tests de dépistage de drogues et des évaluations psychologiques peuvent être utilisés.
Tests de dépistage Benzodiazépines
#3

Quels critères DSM sont liés aux benzazépines ?

Les critères DSM-5 pour le trouble d'usage de substances s'appliquent aux benzazépines.
Trouble d'usage de substances Benzodiazépines
#4

Comment évaluer les effets secondaires des benzazépines ?

L'évaluation se fait par l'observation des symptômes et l'historique médical du patient.
Effets secondaires Benzodiazépines
#5

Quels signes indiquent une surdose de benzazépines ?

Les signes incluent confusion, somnolence excessive, et dépression respiratoire.
Surdose Benzodiazépines

Symptômes 5

#1

Quels sont les symptômes d'une surconsommation de benzazépines ?

Les symptômes incluent somnolence, confusion, et troubles de la coordination.
Symptômes Benzodiazépines
#2

Comment se manifeste le sevrage des benzazépines ?

Le sevrage peut provoquer anxiété, insomnie, tremblements et convulsions.
Sevrage Benzodiazépines
#3

Quels effets à long terme des benzazépines ?

Les effets à long terme peuvent inclure des troubles cognitifs et une dépendance.
Effets à long terme Benzodiazépines
#4

Quels symptômes d'anxiété peuvent être soulagés par les benzazépines ?

Les benzazépines soulagent l'anxiété, les crises de panique et les troubles du sommeil.
Anxiété Benzodiazépines
#5

Les benzazépines causent-elles des troubles de la mémoire ?

Oui, elles peuvent entraîner des troubles de la mémoire, surtout à forte dose.
Troubles de la mémoire Benzodiazépines

Prévention 5

#1

Comment prévenir la dépendance aux benzazépines ?

Limiter la durée de prescription et surveiller l'utilisation sont des mesures préventives.
Prévention Dépendance aux médicaments
#2

Quelles sont les recommandations pour l'utilisation des benzazépines ?

Utiliser à la dose minimale efficace et pour la durée la plus courte possible.
Recommandations Benzodiazépines
#3

Comment éduquer les patients sur les benzazépines ?

Informer sur les risques, les effets secondaires et l'importance du suivi médical.
Éducation des patients Benzodiazépines
#4

Quels sont les risques d'auto-médication avec des benzazépines ?

L'auto-médication peut entraîner des surdoses, des dépendances et des interactions médicamenteuses.
Auto-médication Benzodiazépines
#5

Comment réduire l'usage des benzazépines dans la population ?

Promouvoir des alternatives thérapeutiques et sensibiliser aux risques associés.
Réduction de l'usage Benzodiazépines

Traitements 5

#1

Comment sont prescrites les benzazépines ?

Elles sont prescrites pour des périodes courtes, généralement moins de 4 semaines.
Prescription Benzodiazépines
#2

Quelles alternatives aux benzazépines pour l'anxiété ?

Les antidépresseurs, thérapies cognitives et techniques de relaxation sont des alternatives.
Antidépresseurs Anxiété
#3

Comment gérer une overdose de benzazépines ?

L'overdose nécessite une attention médicale immédiate, souvent avec des antidotes comme le flumazénil.
Overdose Benzodiazépines
#4

Les benzazépines sont-elles efficaces pour l'insomnie ?

Elles sont efficaces à court terme, mais peuvent entraîner une dépendance et des effets secondaires.
Insomnie Benzodiazépines
#5

Quel suivi est nécessaire lors de l'utilisation de benzazépines ?

Un suivi régulier est essentiel pour évaluer l'efficacité et surveiller les effets secondaires.
Suivi médical Benzodiazépines

Complications 5

#1

Quelles complications peuvent survenir avec les benzazépines ?

Les complications incluent la dépendance, les troubles cognitifs et les accidents liés à la somnolence.
Complications Benzodiazépines
#2

Les benzazépines augmentent-elles le risque de chutes ?

Oui, elles augmentent le risque de chutes, surtout chez les personnes âgées.
Chutes Benzodiazépines
#3

Comment les benzazépines affectent-elles la respiration ?

Elles peuvent déprimer le système respiratoire, surtout en cas de surdose.
Dépression respiratoire Benzodiazépines
#4

Les benzazépines peuvent-elles interagir avec d'autres médicaments ?

Oui, elles peuvent interagir avec des opioïdes, des antidépresseurs et d'autres sédatifs.
Interactions médicamenteuses Benzodiazépines
#5

Quels sont les effets des benzazépines sur la grossesse ?

Elles peuvent causer des malformations congénitales et des complications néonatales.
Grossesse Benzodiazépines

Facteurs de risque 5

#1

Quels facteurs augmentent le risque de dépendance aux benzazépines ?

Les antécédents de troubles de l'usage de substances et les troubles mentaux augmentent le risque.
Dépendance Benzodiazépines
#2

Les personnes âgées sont-elles plus à risque avec les benzazépines ?

Oui, elles sont plus sensibles aux effets sédatifs et aux risques de chutes.
Personnes âgées Benzodiazépines
#3

Comment l'usage prolongé de benzazépines affecte-t-il le risque ?

L'usage prolongé augmente le risque de dépendance et de troubles cognitifs.
Usage prolongé Benzodiazépines
#4

Quels facteurs psychologiques influencent l'usage des benzazépines ?

L'anxiété, la dépression et le stress peuvent inciter à l'usage des benzazépines.
Facteurs psychologiques Benzodiazépines
#5

Les interactions médicamenteuses augmentent-elles les risques ?

Oui, certaines interactions peuvent intensifier les effets sédatifs et augmenter le risque d'accidents.
Interactions médicamenteuses Benzodiazépines
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Benzazépines : Questions médicales les plus fréquentes", "headline": "Benzazépines : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Benzazépines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-14", "dateModified": "2025-05-09", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Benzazépines" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Composés hétérobicycliques", "url": "https://questionsmedicales.fr/mesh/D006574", "about": { "@type": "MedicalCondition", "name": "Composés hétérobicycliques", "code": { "@type": "MedicalCode", "code": "D006574", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Benzodiazépines", "alternateName": "Benzodiazepines", "url": "https://questionsmedicales.fr/mesh/D001569", "about": { "@type": "MedicalCondition", "name": "Benzodiazépines", "code": { "@type": "MedicalCode", "code": "D001569", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Alprazolam", "alternateName": "Alprazolam", "url": "https://questionsmedicales.fr/mesh/D000525", "about": { "@type": "MedicalCondition", "name": "Alprazolam", "code": { "@type": "MedicalCode", "code": "D000525", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.030" } } }, { "@type": "MedicalWebPage", "name": "Benzodiazépinones", "alternateName": "Benzodiazepinones", "url": "https://questionsmedicales.fr/mesh/D001570", "about": { "@type": "MedicalCondition", "name": "Benzodiazépinones", "code": { "@type": "MedicalCode", "code": "D001570", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Bromazépam", "alternateName": "Bromazepam", "url": "https://questionsmedicales.fr/mesh/D001960", "about": { "@type": "MedicalCondition", "name": "Bromazépam", "code": { "@type": "MedicalCode", "code": "D001960", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.110" } } }, { "@type": "MedicalWebPage", "name": "Clonazépam", "alternateName": "Clonazepam", "url": "https://questionsmedicales.fr/mesh/D002998", "about": { "@type": "MedicalCondition", "name": "Clonazépam", "code": { "@type": "MedicalCode", "code": "D002998", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.150" } } }, { "@type": "MedicalWebPage", "name": "Dévazépide", "alternateName": "Devazepide", "url": "https://questionsmedicales.fr/mesh/D020109", "about": { "@type": "MedicalCondition", "name": "Dévazépide", "code": { "@type": "MedicalCode", "code": "D020109", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.200" } } }, { "@type": "MedicalWebPage", "name": "Diazépam", "alternateName": "Diazepam", "url": "https://questionsmedicales.fr/mesh/D003975", "about": { "@type": "MedicalCondition", "name": "Diazépam", "code": { "@type": "MedicalCode", "code": "D003975", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.216" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Nordazépam", "alternateName": "Nordazepam", "url": "https://questionsmedicales.fr/mesh/D003708", "about": { "@type": "MedicalCondition", "name": "Nordazépam", "code": { "@type": "MedicalCode", "code": "D003708", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.216.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Nordazépam", "alternateName": "Nordazepam", "url": "https://questionsmedicales.fr/mesh/D003708", "about": { "@type": "MedicalCondition", "name": "Nordazépam", "code": { "@type": "MedicalCode", "code": "D003708", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.216.500" } } }, { "@type": "MedicalWebPage", "name": "Flumazénil", "alternateName": "Flumazenil", "url": "https://questionsmedicales.fr/mesh/D005442", "about": { "@type": "MedicalCondition", "name": "Flumazénil", "code": { "@type": "MedicalCode", "code": "D005442", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.305" } } }, { "@type": "MedicalWebPage", "name": "Flunitrazépam", "alternateName": "Flunitrazepam", "url": "https://questionsmedicales.fr/mesh/D005445", "about": { "@type": "MedicalCondition", "name": "Flunitrazépam", "code": { "@type": "MedicalCode", "code": "D005445", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.320" } } }, { "@type": "MedicalWebPage", "name": "Flurazépam", "alternateName": "Flurazepam", "url": "https://questionsmedicales.fr/mesh/D005479", "about": { "@type": "MedicalCondition", "name": "Flurazépam", "code": { "@type": "MedicalCode", "code": "D005479", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.348" } } }, { "@type": "MedicalWebPage", "name": "Lorazépam", "alternateName": "Lorazepam", "url": "https://questionsmedicales.fr/mesh/D008140", "about": { "@type": "MedicalCondition", "name": "Lorazépam", "code": { "@type": "MedicalCode", "code": "D008140", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.450" } } }, { "@type": "MedicalWebPage", "name": "Nitrazépam", "alternateName": "Nitrazepam", "url": "https://questionsmedicales.fr/mesh/D009567", "about": { "@type": "MedicalCondition", "name": "Nitrazépam", "code": { "@type": "MedicalCode", "code": "D009567", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.565" } } }, { "@type": "MedicalWebPage", "name": "Oxazépam", "alternateName": "Oxazepam", "url": "https://questionsmedicales.fr/mesh/D010076", "about": { "@type": "MedicalCondition", "name": "Oxazépam", "code": { "@type": "MedicalCode", "code": "D010076", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.663" } } }, { "@type": "MedicalWebPage", "name": "Pirenzépine", "alternateName": "Pirenzepine", "url": "https://questionsmedicales.fr/mesh/D010890", "about": { "@type": "MedicalCondition", "name": "Pirenzépine", "code": { "@type": "MedicalCode", "code": "D010890", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.750" } } }, { "@type": "MedicalWebPage", "name": "Prazépam", "alternateName": "Prazepam", "url": "https://questionsmedicales.fr/mesh/D011222", "about": { "@type": "MedicalCondition", "name": "Prazépam", "code": { "@type": "MedicalCode", "code": "D011222", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.784" } } }, { "@type": "MedicalWebPage", "name": "Témazépam", "alternateName": "Temazepam", "url": "https://questionsmedicales.fr/mesh/D013693", "about": { "@type": "MedicalCondition", "name": "Témazépam", "code": { "@type": "MedicalCode", "code": "D013693", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.880" } } } ] }, { "@type": "MedicalWebPage", "name": "Bromazépam", "alternateName": "Bromazepam", "url": "https://questionsmedicales.fr/mesh/D001960", "about": { "@type": "MedicalCondition", "name": "Bromazépam", "code": { "@type": "MedicalCode", "code": "D001960", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.110" } } }, { "@type": "MedicalWebPage", "name": "Clonazépam", "alternateName": "Clonazepam", "url": "https://questionsmedicales.fr/mesh/D002998", "about": { "@type": "MedicalCondition", "name": "Clonazépam", "code": { "@type": "MedicalCode", "code": "D002998", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.150" } } }, { "@type": "MedicalWebPage", "name": "Dévazépide", "alternateName": "Devazepide", "url": "https://questionsmedicales.fr/mesh/D020109", "about": { "@type": "MedicalCondition", "name": "Dévazépide", "code": { "@type": "MedicalCode", "code": "D020109", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.200" } } }, { "@type": "MedicalWebPage", "name": "Diazépam", "alternateName": "Diazepam", "url": "https://questionsmedicales.fr/mesh/D003975", "about": { "@type": "MedicalCondition", "name": "Diazépam", "code": { "@type": "MedicalCode", "code": "D003975", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.216" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Nordazépam", "alternateName": "Nordazepam", "url": "https://questionsmedicales.fr/mesh/D003708", "about": { "@type": "MedicalCondition", "name": "Nordazépam", "code": { "@type": "MedicalCode", "code": "D003708", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.216.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Nordazépam", "alternateName": "Nordazepam", "url": "https://questionsmedicales.fr/mesh/D003708", "about": { "@type": "MedicalCondition", "name": "Nordazépam", "code": { "@type": "MedicalCode", "code": "D003708", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.216.500" } } }, { "@type": "MedicalWebPage", "name": "Flumazénil", "alternateName": "Flumazenil", "url": "https://questionsmedicales.fr/mesh/D005442", "about": { "@type": "MedicalCondition", "name": "Flumazénil", "code": { "@type": "MedicalCode", "code": "D005442", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.305" } } }, { "@type": "MedicalWebPage", "name": "Flunitrazépam", "alternateName": "Flunitrazepam", "url": "https://questionsmedicales.fr/mesh/D005445", "about": { "@type": "MedicalCondition", "name": "Flunitrazépam", "code": { "@type": "MedicalCode", "code": "D005445", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.320" } } }, { "@type": "MedicalWebPage", "name": "Flurazépam", "alternateName": "Flurazepam", "url": "https://questionsmedicales.fr/mesh/D005479", "about": { "@type": "MedicalCondition", "name": "Flurazépam", "code": { "@type": "MedicalCode", "code": "D005479", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.348" } } }, { "@type": "MedicalWebPage", "name": "Lorazépam", "alternateName": "Lorazepam", "url": "https://questionsmedicales.fr/mesh/D008140", "about": { "@type": "MedicalCondition", "name": "Lorazépam", "code": { "@type": "MedicalCode", "code": "D008140", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.450" } } }, { "@type": "MedicalWebPage", "name": "Nitrazépam", "alternateName": "Nitrazepam", "url": "https://questionsmedicales.fr/mesh/D009567", "about": { "@type": "MedicalCondition", "name": "Nitrazépam", "code": { "@type": "MedicalCode", "code": "D009567", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.565" } } }, { "@type": "MedicalWebPage", "name": "Oxazépam", "alternateName": "Oxazepam", "url": "https://questionsmedicales.fr/mesh/D010076", "about": { "@type": "MedicalCondition", "name": "Oxazépam", "code": { "@type": "MedicalCode", "code": "D010076", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.663" } } }, { "@type": "MedicalWebPage", "name": "Pirenzépine", "alternateName": "Pirenzepine", "url": "https://questionsmedicales.fr/mesh/D010890", "about": { "@type": "MedicalCondition", "name": "Pirenzépine", "code": { "@type": "MedicalCode", "code": "D010890", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.750" } } }, { "@type": "MedicalWebPage", "name": "Prazépam", "alternateName": "Prazepam", "url": "https://questionsmedicales.fr/mesh/D011222", "about": { "@type": "MedicalCondition", "name": "Prazépam", "code": { "@type": "MedicalCode", "code": "D011222", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.784" } } }, { "@type": "MedicalWebPage", "name": "Témazépam", "alternateName": "Temazepam", "url": "https://questionsmedicales.fr/mesh/D013693", "about": { "@type": "MedicalCondition", "name": "Témazépam", "code": { "@type": "MedicalCode", "code": "D013693", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.880" } } }, { "@type": "MedicalWebPage", "name": "Chlordiazépoxyde", "alternateName": "Chlordiazepoxide", "url": "https://questionsmedicales.fr/mesh/D002707", "about": { "@type": "MedicalCondition", "name": "Chlordiazépoxyde", "code": { "@type": "MedicalCode", "code": "D002707", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.150" } } }, { "@type": "MedicalWebPage", "name": "Clobazam", "alternateName": "Clobazam", "url": "https://questionsmedicales.fr/mesh/D000078306", "about": { "@type": "MedicalCondition", "name": "Clobazam", "code": { "@type": "MedicalCode", "code": "D000078306", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.165" } } }, { "@type": "MedicalWebPage", "name": "Clorazépate dipotassique", "alternateName": "Clorazepate Dipotassium", "url": "https://questionsmedicales.fr/mesh/D003009", "about": { "@type": "MedicalCondition", "name": "Clorazépate dipotassique", "code": { "@type": "MedicalCode", "code": "D003009", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.180" } } }, { "@type": "MedicalWebPage", "name": "Estazolam", "alternateName": "Estazolam", "url": "https://questionsmedicales.fr/mesh/D004949", "about": { "@type": "MedicalCondition", "name": "Estazolam", "code": { "@type": "MedicalCode", "code": "D004949", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.250" } } }, { "@type": "MedicalWebPage", "name": "Médazépam", "alternateName": "Medazepam", "url": "https://questionsmedicales.fr/mesh/D008472", "about": { "@type": "MedicalCondition", "name": "Médazépam", "code": { "@type": "MedicalCode", "code": "D008472", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.550" } } }, { "@type": "MedicalWebPage", "name": "Midazolam", "alternateName": "Midazolam", "url": "https://questionsmedicales.fr/mesh/D008874", "about": { "@type": "MedicalCondition", "name": "Midazolam", "code": { "@type": "MedicalCode", "code": "D008874", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.575" } } }, { "@type": "MedicalWebPage", "name": "Olanzapine", "alternateName": "Olanzapine", "url": "https://questionsmedicales.fr/mesh/D000077152", "about": { "@type": "MedicalCondition", "name": "Olanzapine", "code": { "@type": "MedicalCode", "code": "D000077152", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.738" } } }, { "@type": "MedicalWebPage", "name": "Triazolam", "alternateName": "Triazolam", "url": "https://questionsmedicales.fr/mesh/D014229", "about": { "@type": "MedicalCondition", "name": "Triazolam", "code": { "@type": "MedicalCode", "code": "D014229", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.900" } } } ] }, { "@type": "MedicalWebPage", "name": "Diltiazem", "alternateName": "Diltiazem", "url": "https://questionsmedicales.fr/mesh/D004110", "about": { "@type": "MedicalCondition", "name": "Diltiazem", "code": { "@type": "MedicalCode", "code": "D004110", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.150" } } }, { "@type": "MedicalWebPage", "name": "Fénoldopam", "alternateName": "Fenoldopam", "url": "https://questionsmedicales.fr/mesh/D018818", "about": { "@type": "MedicalCondition", "name": "Fénoldopam", "code": { "@type": "MedicalCode", "code": "D018818", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.300" } } }, { "@type": "MedicalWebPage", "name": "Galantamine", "alternateName": "Galantamine", "url": "https://questionsmedicales.fr/mesh/D005702", "about": { "@type": "MedicalCondition", "name": "Galantamine", "code": { "@type": "MedicalCode", "code": "D005702", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.525" } } }, { "@type": "MedicalWebPage", "name": "Ivabradine", "alternateName": "Ivabradine", "url": "https://questionsmedicales.fr/mesh/D000077550", "about": { "@type": "MedicalCondition", "name": "Ivabradine", "code": { "@type": "MedicalCode", "code": "D000077550", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.801" } } }, { "@type": "MedicalWebPage", "name": "1-Phényl-2,3,4,5-tétrahydro-1H-3-benzazépine-7,8-diol", "alternateName": "2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine", "url": "https://questionsmedicales.fr/mesh/D015647", "about": { "@type": "MedicalCondition", "name": "1-Phényl-2,3,4,5-tétrahydro-1H-3-benzazépine-7,8-diol", "code": { "@type": "MedicalCode", "code": "D015647", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.838" } } }, { "@type": "MedicalWebPage", "name": "Tolvaptan", "alternateName": "Tolvaptan", "url": "https://questionsmedicales.fr/mesh/D000077602", "about": { "@type": "MedicalCondition", "name": "Tolvaptan", "code": { "@type": "MedicalCode", "code": "D000077602", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.875" } } } ], "about": { "@type": "MedicalCondition", "name": "Benzazépines", "alternateName": "Benzazepines", "code": { "@type": "MedicalCode", "code": "D001552", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Bernhard Wünsch", "url": "https://questionsmedicales.fr/author/Bernhard%20W%C3%BCnsch", "affiliation": { "@type": "Organization", "name": "Institute of Pharmaceutical and Medicinal Chemistry, University of Münster, Münster, Germany." } }, { "@type": "Person", "name": "Dirk Schepmann", "url": "https://questionsmedicales.fr/author/Dirk%20Schepmann", "affiliation": { "@type": "Organization", "name": "Institute of Pharmaceutical and Medicinal Chemistry, University of Münster, Corrensstr. 48, 48149, Münster, Germany." } }, { "@type": "Person", "name": "Simon M Ametamey", "url": "https://questionsmedicales.fr/author/Simon%20M%20Ametamey", "affiliation": { "@type": "Organization", "name": "Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland simon.ametamey@pharma.ethz.ch." } }, { "@type": "Person", "name": "Nadine Ritter", "url": "https://questionsmedicales.fr/author/Nadine%20Ritter", "affiliation": { "@type": "Organization", "name": "Institute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, 48149, Münster, Germany. nadine.ritter@uni-muenster.de." } }, { "@type": "Person", "name": "Guiscard Seebohm", "url": "https://questionsmedicales.fr/author/Guiscard%20Seebohm", "affiliation": { "@type": "Organization", "name": "Institute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, 48149, Münster, Germany." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Norepinephrine activates β", "datePublished": "2022-05-19", "url": "https://questionsmedicales.fr/article/35589612", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/glia.24219" } }, { "@type": "ScholarlyArticle", "name": "Norepinephrine combined with phenylephrine versus norepinephrine in patients with septic shock: a retrospective cohort study.", "datePublished": "2023-04-07", "url": "https://questionsmedicales.fr/article/37029365", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12879-023-08142-x" } }, { "@type": "ScholarlyArticle", "name": "Norepinephrine system at the interface of attention and reward.", "datePublished": "2023-03-16", "url": "https://questionsmedicales.fr/article/36933778", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.pnpbp.2023.110751" } }, { "@type": "ScholarlyArticle", "name": "Combination of norepinephrine with phenylephrine versus norepinephrine with vasopressin in critically ill patients with septic shock: A retrospective study.", "datePublished": "2022-07-28", "url": "https://questionsmedicales.fr/article/35908329", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jcrc.2022.154121" } }, { "@type": "ScholarlyArticle", "name": "Peripheral Administration of Norepinephrine: A Prospective Observational Study.", "datePublished": "2023-08-21", "url": "https://questionsmedicales.fr/article/37611862", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.chest.2023.08.019" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés hétérocycliques", "item": "https://questionsmedicales.fr/mesh/D006571" }, { "@type": "ListItem", "position": 3, "name": "Composés hétérocycliques à cycles fusionnés", "item": "https://questionsmedicales.fr/mesh/D000072471" }, { "@type": "ListItem", "position": 4, "name": "Composés hétérobicycliques", "item": "https://questionsmedicales.fr/mesh/D006574" }, { "@type": "ListItem", "position": 5, "name": "Benzazépines", "item": "https://questionsmedicales.fr/mesh/D001552" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Benzazépines - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Benzazépines", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-09", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Benzazépines", "description": "Comment diagnostiquer une dépendance aux benzazépines ?\nQuels tests sont utilisés pour évaluer l'usage des benzazépines ?\nQuels critères DSM sont liés aux benzazépines ?\nComment évaluer les effets secondaires des benzazépines ?\nQuels signes indiquent une surdose de benzazépines ?", "url": "https://questionsmedicales.fr/mesh/D001552?mesh_terms=Norepinephrine#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Benzazépines", "description": "Quels sont les symptômes d'une surconsommation de benzazépines ?\nComment se manifeste le sevrage des benzazépines ?\nQuels effets à long terme des benzazépines ?\nQuels symptômes d'anxiété peuvent être soulagés par les benzazépines ?\nLes benzazépines causent-elles des troubles de la mémoire ?", "url": "https://questionsmedicales.fr/mesh/D001552?mesh_terms=Norepinephrine#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Benzazépines", "description": "Comment prévenir la dépendance aux benzazépines ?\nQuelles sont les recommandations pour l'utilisation des benzazépines ?\nComment éduquer les patients sur les benzazépines ?\nQuels sont les risques d'auto-médication avec des benzazépines ?\nComment réduire l'usage des benzazépines dans la population ?", "url": "https://questionsmedicales.fr/mesh/D001552?mesh_terms=Norepinephrine#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Benzazépines", "description": "Comment sont prescrites les benzazépines ?\nQuelles alternatives aux benzazépines pour l'anxiété ?\nComment gérer une overdose de benzazépines ?\nLes benzazépines sont-elles efficaces pour l'insomnie ?\nQuel suivi est nécessaire lors de l'utilisation de benzazépines ?", "url": "https://questionsmedicales.fr/mesh/D001552?mesh_terms=Norepinephrine#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Benzazépines", "description": "Quelles complications peuvent survenir avec les benzazépines ?\nLes benzazépines augmentent-elles le risque de chutes ?\nComment les benzazépines affectent-elles la respiration ?\nLes benzazépines peuvent-elles interagir avec d'autres médicaments ?\nQuels sont les effets des benzazépines sur la grossesse ?", "url": "https://questionsmedicales.fr/mesh/D001552?mesh_terms=Norepinephrine#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Benzazépines", "description": "Quels facteurs augmentent le risque de dépendance aux benzazépines ?\nLes personnes âgées sont-elles plus à risque avec les benzazépines ?\nComment l'usage prolongé de benzazépines affecte-t-il le risque ?\nQuels facteurs psychologiques influencent l'usage des benzazépines ?\nLes interactions médicamenteuses augmentent-elles les risques ?", "url": "https://questionsmedicales.fr/mesh/D001552?mesh_terms=Norepinephrine#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dépendance aux benzazépines ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'historique d'utilisation, les symptômes de sevrage et les comportements compulsifs." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'usage des benzazépines ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de dépistage de drogues et des évaluations psychologiques peuvent être utilisés." } }, { "@type": "Question", "name": "Quels critères DSM sont liés aux benzazépines ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les critères DSM-5 pour le trouble d'usage de substances s'appliquent aux benzazépines." } }, { "@type": "Question", "name": "Comment évaluer les effets secondaires des benzazépines ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'évaluation se fait par l'observation des symptômes et l'historique médical du patient." } }, { "@type": "Question", "name": "Quels signes indiquent une surdose de benzazépines ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent confusion, somnolence excessive, et dépression respiratoire." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une surconsommation de benzazépines ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent somnolence, confusion, et troubles de la coordination." } }, { "@type": "Question", "name": "Comment se manifeste le sevrage des benzazépines ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Le sevrage peut provoquer anxiété, insomnie, tremblements et convulsions." } }, { "@type": "Question", "name": "Quels effets à long terme des benzazépines ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les effets à long terme peuvent inclure des troubles cognitifs et une dépendance." } }, { "@type": "Question", "name": "Quels symptômes d'anxiété peuvent être soulagés par les benzazépines ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Les benzazépines soulagent l'anxiété, les crises de panique et les troubles du sommeil." } }, { "@type": "Question", "name": "Les benzazépines causent-elles des troubles de la mémoire ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent entraîner des troubles de la mémoire, surtout à forte dose." } }, { "@type": "Question", "name": "Comment prévenir la dépendance aux benzazépines ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Limiter la durée de prescription et surveiller l'utilisation sont des mesures préventives." } }, { "@type": "Question", "name": "Quelles sont les recommandations pour l'utilisation des benzazépines ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Utiliser à la dose minimale efficace et pour la durée la plus courte possible." } }, { "@type": "Question", "name": "Comment éduquer les patients sur les benzazépines ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Informer sur les risques, les effets secondaires et l'importance du suivi médical." } }, { "@type": "Question", "name": "Quels sont les risques d'auto-médication avec des benzazépines ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "L'auto-médication peut entraîner des surdoses, des dépendances et des interactions médicamenteuses." } }, { "@type": "Question", "name": "Comment réduire l'usage des benzazépines dans la population ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Promouvoir des alternatives thérapeutiques et sensibiliser aux risques associés." } }, { "@type": "Question", "name": "Comment sont prescrites les benzazépines ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont prescrites pour des périodes courtes, généralement moins de 4 semaines." } }, { "@type": "Question", "name": "Quelles alternatives aux benzazépines pour l'anxiété ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Les antidépresseurs, thérapies cognitives et techniques de relaxation sont des alternatives." } }, { "@type": "Question", "name": "Comment gérer une overdose de benzazépines ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "L'overdose nécessite une attention médicale immédiate, souvent avec des antidotes comme le flumazénil." } }, { "@type": "Question", "name": "Les benzazépines sont-elles efficaces pour l'insomnie ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont efficaces à court terme, mais peuvent entraîner une dépendance et des effets secondaires." } }, { "@type": "Question", "name": "Quel suivi est nécessaire lors de l'utilisation de benzazépines ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Un suivi régulier est essentiel pour évaluer l'efficacité et surveiller les effets secondaires." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec les benzazépines ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent la dépendance, les troubles cognitifs et les accidents liés à la somnolence." } }, { "@type": "Question", "name": "Les benzazépines augmentent-elles le risque de chutes ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles augmentent le risque de chutes, surtout chez les personnes âgées." } }, { "@type": "Question", "name": "Comment les benzazépines affectent-elles la respiration ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent déprimer le système respiratoire, surtout en cas de surdose." } }, { "@type": "Question", "name": "Les benzazépines peuvent-elles interagir avec d'autres médicaments ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent interagir avec des opioïdes, des antidépresseurs et d'autres sédatifs." } }, { "@type": "Question", "name": "Quels sont les effets des benzazépines sur la grossesse ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent causer des malformations congénitales et des complications néonatales." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque de dépendance aux benzazépines ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents de troubles de l'usage de substances et les troubles mentaux augmentent le risque." } }, { "@type": "Question", "name": "Les personnes âgées sont-elles plus à risque avec les benzazépines ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles sont plus sensibles aux effets sédatifs et aux risques de chutes." } }, { "@type": "Question", "name": "Comment l'usage prolongé de benzazépines affecte-t-il le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "L'usage prolongé augmente le risque de dépendance et de troubles cognitifs." } }, { "@type": "Question", "name": "Quels facteurs psychologiques influencent l'usage des benzazépines ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "L'anxiété, la dépression et le stress peuvent inciter à l'usage des benzazépines." } }, { "@type": "Question", "name": "Les interactions médicamenteuses augmentent-elles les risques ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines interactions peuvent intensifier les effets sédatifs et augmenter le risque d'accidents." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale

Validation scientifique effectuée le 09/05/2025

Contenu vérifié selon les dernières recommandations médicales

En savoir plus sur Dr Menir

Sous-catégories

31 au total
└─

Benzodiazépines

Benzodiazepines D001569 - D03.633.100.079.080
└─

Diltiazem

Diltiazem D004110 - D03.633.100.079.150
└─

Fénoldopam

Fenoldopam D018818 - D03.633.100.079.300
└─

Galantamine

Galantamine D005702 - D03.633.100.079.525
└─

Ivabradine

Ivabradine D000077550 - D03.633.100.079.801
└─

1-Phényl-2,3,4,5-tétrahydro-1H-3-benzazépine-7,8-diol

2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine D015647 - D03.633.100.079.838
└─

Tolvaptan

Tolvaptan D000077602 - D03.633.100.079.875
└─└─

Alprazolam

Alprazolam D000525 - D03.633.100.079.080.030
└─└─

Benzodiazépinones

Benzodiazepinones D001570 - D03.633.100.079.080.070
└─└─

Chlordiazépoxyde

Chlordiazepoxide D002707 - D03.633.100.079.080.150
└─└─

Clobazam

Clobazam D000078306 - D03.633.100.079.080.165
└─└─

Clorazépate dipotassique

Clorazepate Dipotassium D003009 - D03.633.100.079.080.180
└─└─

Estazolam

Estazolam D004949 - D03.633.100.079.080.250
└─└─

Médazépam

Medazepam D008472 - D03.633.100.079.080.550
└─└─

Midazolam

Midazolam D008874 - D03.633.100.079.080.575
└─└─

Olanzapine

Olanzapine D000077152 - D03.633.100.079.080.738
└─└─

Triazolam

Triazolam D014229 - D03.633.100.079.080.900
└─└─└─

Bromazépam

Bromazepam D001960 - D03.633.100.079.080.070.110
└─└─└─

Clonazépam

Clonazepam D002998 - D03.633.100.079.080.070.150
└─└─└─

Dévazépide

Devazepide D020109 - D03.633.100.079.080.070.200
└─└─└─

Diazépam

Diazepam D003975 - D03.633.100.079.080.070.216
└─└─└─

Flumazénil

Flumazenil D005442 - D03.633.100.079.080.070.305
└─└─└─

Flunitrazépam

Flunitrazepam D005445 - D03.633.100.079.080.070.320
└─└─└─

Flurazépam

Flurazepam D005479 - D03.633.100.079.080.070.348
└─└─└─

Lorazépam

Lorazepam D008140 - D03.633.100.079.080.070.450
└─└─└─

Nitrazépam

Nitrazepam D009567 - D03.633.100.079.080.070.565
└─└─└─

Oxazépam

Oxazepam D010076 - D03.633.100.079.080.070.663
└─└─└─

Pirenzépine

Pirenzepine D010890 - D03.633.100.079.080.070.750
└─└─└─

Prazépam

Prazepam D011222 - D03.633.100.079.080.070.784
└─└─└─

Témazépam

Temazepam D013693 - D03.633.100.079.080.070.880
└─└─└─└─

Nordazépam

Nordazepam D003708 - D03.633.100.079.080.070.216.500

Auteurs principaux

Bernhard Wünsch

9 publications dans cette catégorie

Affiliations :
  • Institute of Pharmaceutical and Medicinal Chemistry, University of Münster, Münster, Germany.
Publications dans "Benzazépines" : Voir toutes les publications (9)

Dirk Schepmann

7 publications dans cette catégorie

Affiliations :
  • Institute of Pharmaceutical and Medicinal Chemistry, University of Münster, Corrensstr. 48, 48149, Münster, Germany.
Publications dans "Benzazépines" : Voir toutes les publications (7)

Simon M Ametamey

5 publications dans cette catégorie

Affiliations :
  • Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland simon.ametamey@pharma.ethz.ch.
Publications dans "Benzazépines" :

Nadine Ritter

3 publications dans cette catégorie

Affiliations :
  • Institute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, 48149, Münster, Germany. nadine.ritter@uni-muenster.de.
  • Chembion, University of Münster, 48149, Münster, Germany. nadine.ritter@uni-muenster.de.
Publications dans "Benzazépines" :

Guiscard Seebohm

3 publications dans cette catégorie

Affiliations :
  • Institute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, 48149, Münster, Germany.
  • Chembion, University of Münster, 48149, Münster, Germany.
Publications dans "Benzazépines" :

Alexander Markus

3 publications dans cette catégorie

Affiliations :
  • Institut für Pharmazeutische und Medizinische Chemie der Universität Münster, Münster, Germany.
Publications dans "Benzazépines" :

Paul Disse

2 publications dans cette catégorie

Affiliations :
  • Institute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, 48149, Münster, Germany.
  • Chembion, University of Münster, 48149, Münster, Germany.
Publications dans "Benzazépines" :

Julian A Schreiber

2 publications dans cette catégorie

Affiliations :
  • Institute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, 48149, Münster, Germany.
  • Institute of Pharmaceutical and Medicinal Chemistry, University of Münster, Corrensstr. 48, 48149, Münster, Germany.
Publications dans "Benzazépines" :

Nathalie Strutz-Seebohm

2 publications dans cette catégorie

Affiliations :
  • Institute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, 48149, Münster, Germany.
Publications dans "Benzazépines" :

Nengneng Zhou

2 publications dans cette catégorie

Affiliations :
  • Key Laboratory of Functionalized Molecular Solids, Ministry of Education, Anhui Key Laboratory of Molecule-Based Materials, College of Chemistry and Materials Science, Anhui Normal University, Wuhu, Anhui 241000, China.
Publications dans "Benzazépines" :

Fangli Zhao

2 publications dans cette catégorie

Affiliations :
  • Key Laboratory of Functionalized Molecular Solids, Ministry of Education, Anhui Key Laboratory of Molecule-Based Materials, College of Chemistry and Materials Science, Anhui Normal University, Wuhu, Anhui 241000, China.
Publications dans "Benzazépines" :

Lei Wang

2 publications dans cette catégorie

Affiliations :
  • Key Laboratory of Functionalized Molecular Solids, Ministry of Education, Anhui Key Laboratory of Molecule-Based Materials, College of Chemistry and Materials Science, Anhui Normal University, Wuhu, Anhui 241000, China.
Publications dans "Benzazépines" :

Xiang Gao

2 publications dans cette catégorie

Affiliations :
  • Key Laboratory of Functionalized Molecular Solids, Ministry of Education, Anhui Key Laboratory of Molecule-Based Materials, College of Chemistry and Materials Science, Anhui Normal University, Wuhu, Anhui 241000, China.
Publications dans "Benzazépines" :

Xiaowei Zhao

2 publications dans cette catégorie

Affiliations :
  • Key Laboratory of Functionalized Molecular Solids, Ministry of Education, Anhui Key Laboratory of Molecule-Based Materials, College of Chemistry and Materials Science, Anhui Normal University, Wuhu, Anhui 241000, China.
Publications dans "Benzazépines" :

Man Zhang

2 publications dans cette catégorie

Affiliations :
  • Key Laboratory of Functionalized Molecular Solids, Ministry of Education, Anhui Key Laboratory of Molecule-Based Materials, College of Chemistry and Materials Science, Anhui Normal University, Wuhu, Anhui 241000, China.
Publications dans "Benzazépines" :

Álvaro Velasco-Rubio

2 publications dans cette catégorie

Affiliations :
  • Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.
Publications dans "Benzazépines" :

Jesús A Varela

2 publications dans cette catégorie

Affiliations :
  • Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.
Publications dans "Benzazépines" :

Carlos Saá

2 publications dans cette catégorie

Affiliations :
  • Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.
Publications dans "Benzazépines" :

Yoshikazu Arai

2 publications dans cette catégorie

Affiliations :
  • End-Organ Disease Laboratories, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan. Electronic address: arai.yoshikazu.mh@daiichisankyo.co.jp.
Publications dans "Benzazépines" :

Yohei Kiyotsuka

2 publications dans cette catégorie

Affiliations :
  • End-Organ Disease Laboratories, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan.
Publications dans "Benzazépines" :

Sources (540 au total)

Norepinephrine combined with phenylephrine versus norepinephrine in patients with septic shock: a retrospective cohort study.

07 Apr 2023
DOI: 10.1186/s12879-023-08142-x PMID: 37029365

Phenylephrine (PE) and norepinephrine (NE) may be used to maintain adequate blood pressure and tissue perfusion in patients with septic shock, but the effect of NE combined with PE (NE-PE) on mortalit... This single-center, retrospective cohort study included adult patients with septic shock. According to the infusion type, patients were divided into the NE-PE or NE group. Multivariate logistic regres... Among 1, 747 included patients, 1, 055 received NE and 692 received NE-PE. For the primary outcome, the hospital mortality rate was higher in patients who received NE-PE than in those who received NE ... NE combined with PE was inferior to NE alone in patients with septic shock, and it was associated with a higher hospital mortality rate....

Adult Humans Norepinephrine Phenylephrine Shock, Septic +2 autres

Combination of norepinephrine with phenylephrine versus norepinephrine with vasopressin in critically ill patients with septic shock: A retrospective study.

12 2022
DOI: 10.1016/j.jcrc.2022.154121 PMID: 35908329

To evaluate the outcomes of patients with septic shock treated with a combination of norepinephrine with phenylephrine compared to norepinephrine with vasopressin.... This was a retrospective cohort study including adults admitted between 2002 and 2017 with septic shock according to the Sepsis 3 criteria. We compared outcomes of patients treated with norepinephrine... During the study period, 158 patients with septic shock were treated with norepinephrine with phenylephrine and 129 with norepinephrine with vasopressin. Crude in-hospital mortality was not different ... Phenylephrine used as a second-line vasoactive agent combined with norepinephrine may be a reasonable option compared to vasopressin. However, this finding needs to be validated in a randomized contro...

Adult Humans Norepinephrine Shock, Septic Phenylephrine +4 autres

Peripheral Administration of Norepinephrine: A Prospective Observational Study.

Feb 2024
DOI: 10.1016/j.chest.2023.08.019 PMID: 37611862

Historically, norepinephrine has been administered through a central venous catheter (CVC) because of concerns about the risk of ischemic tissue injury if extravasation from a peripheral IV catheter (... Can a protocol for peripheral norepinephrine administration safely reduce the number of days a CVC is in use and frequency of CVC placement?... This was a prospective observational cohort study conducted in the medical ICU at a quaternary care academic medical center. A protocol for peripheral norepinephrine administration was developed and i... The primary outcome was the number of days of CVC use that were avoided per patient, and the secondary safety outcomes included the incidence of extravasation events. Six hundred thirty-five patients ... This study suggests that implementing a protocol for peripheral administration of norepinephrine safely can avoid 1 CVC day in the average patient, with 51.6% of patients not requiring CVC insertion. ...

Adult Humans Norepinephrine Prospective Studies Central Venous Catheters +2 autres

The Association of Norepinephrine Utilization With Mortality Risk in Trauma Patients.

12 2022
DOI: 10.1016/j.jss.2022.06.042 PMID: 36007482

While the pillars of trauma resuscitation are surgical hemostasis and blood product administration, norepinephrine (NE) can be used as an adjunct. The goal of this study was to evaluate the relationsh... Patients admitted between January 2013 and January 2021 treated with NE were reviewed. Univariate and multivariate logistic regression were used to assess whether maximum NE dose was independently ass... Three hundred fifty-first trauma patients were included, with 217 (62%) surviving. Patients who died received an average maximum dose of 16.7 mcg/min compared to 9.1 mcg/min in survivors (P = 0.0003).... Higher maximum doses of NE were associated with increased mortality. Patients initiated on NE more than 24 h into their admission displayed an inflection point at a lower dose than those initiated lat...

Humans Norepinephrine Vasoconstrictor Agents Resuscitation